Compare Abeona Therapeutics Inc (ABEO) vs FMC Corp (FMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs FMC Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while FMC Corp trades at $10.99 (market cap $1.45B). The key difference: FMC Corp is far larger — about 3.9× Abeona Therapeutics Inc's market cap, and FMC Corp pays a 2.76% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FMC | |
|---|---|---|
Market Cap | $373.32M | $1.45B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $43.90 |
52-Week Low | $4.17 | $10.80 |
Enterprise Value | $228.22M | $5.59B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FMC Corporation trades at $11.59, up 2.11% today, but remains in a bearish technical trend. The company reported a net loss of -$2.24 billion in 2025 with negative margins, though recent strategic moves include a $400 million minority investment from Tessenderlo Group and asset sales to reduce debt. Analyst consensus is mixed with a $17.00 price target, suggesting potential upside from current levels.
The outlook hinges on successful debt reduction and operational turnaround. Investment opportunity exists if cost-cutting and partnerships restore profitability, but risks include persistent revenue declines, high leverage, and competitive pressures in the agricultural sciences sector. Execution on strategic initiatives is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
